Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Rhabdomyosarcoma × Vinorelbine × Clear all

Phase

Phase 2 3 Phase 3 2 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Sarcoma 3 Neoplasm Metastasis 3 Lung Neoplasms 3 Hodgkin Disease 3 Carcinoma, Non-Small-Cell Lung 3 Small Cell Lung Carcinoma 2 Recurrence 2 Neoplasms 2 Lymphoma 2 Rhabdomyosarcoma 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Fibrosarcoma 1 Desmoplastic Small Round Cell Tumor 1 Burkitt Lymphoma 1 Brain Neoplasms 1

Interventions

Temozolomide 8 Irinotecan 7 Vincristine 6 Nivolumab 2 temsirolimus 1 talazoparib 1 surufatinib 1 silmitasertib 1 regorafenib 1 prexasertib 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 liposomal doxorubicin 1 lenvatinib 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 irinotecan sucrosofate 1 ganitumab 1 eribulin 1 efineptakin alfa 1 dostarlimab 1 dinutuximab 1 copanlisib 1 bempegaldesleukin 1 atezolizumab 1 adavosertib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Thrombopoietin 1 Receptor Protein-Tyrosine Kinases 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04625907 2024-05-23

FaR-RMS

University of Birmingham

Phase 1/2 Recruiting

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡